BR112017024073A2 - métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase - Google Patents
métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinaseInfo
- Publication number
- BR112017024073A2 BR112017024073A2 BR112017024073-4A BR112017024073A BR112017024073A2 BR 112017024073 A2 BR112017024073 A2 BR 112017024073A2 BR 112017024073 A BR112017024073 A BR 112017024073A BR 112017024073 A2 BR112017024073 A2 BR 112017024073A2
- Authority
- BR
- Brazil
- Prior art keywords
- egf
- once
- combination
- antibodies
- egfr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108060006698 EGF receptor Proteins 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 abstract 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
um método para tratar pacientes que sofrem de cânceres conduzidos pelo receptor de fator de crescimento epidérmico humano (her1/egfr humano) desregulado compreendendo a administração a um paciente em necessidade de tal tratamento de um regime flexível e ativo para a combinação de um inibidor da tirosina quinase (tki) e anticorpos anti-egf para a inibição da via ativada por ligação de egf-egfr (mab). os anticorpos anti-egf podem ser produzidos por imunização ativa ou desde que passivamente pela administração de anticorpos que sejam anti-egf. o método compreende o tki administrado de acordo com um regime contínuo com base em uma dose diária média na faixa de 10 a 150 mg e o mab é coadministrado de forma ativa ou passiva de acordo com um regime de dosagem que alcance uma quantidade eficaz terapêutica repetida três vezes, duas vezes ou uma vez por semana, uma vez em duas semanas, uma vez em três semanas ou pelo menos uma vez por mês.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160183P | 2015-05-12 | 2015-05-12 | |
| US62/160,183 | 2015-05-12 | ||
| US15/073,021 US20160333087A1 (en) | 2015-05-12 | 2016-03-17 | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
| US15/073,021 | 2016-03-17 | ||
| PCT/IB2016/000888 WO2016181225A2 (en) | 2015-05-12 | 2016-05-12 | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017024073A2 true BR112017024073A2 (pt) | 2018-07-24 |
Family
ID=56497806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017024073-4A BR112017024073A2 (pt) | 2015-05-12 | 2016-05-12 | métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160333087A1 (pt) |
| EP (1) | EP3294327A2 (pt) |
| JP (3) | JP7291987B2 (pt) |
| KR (1) | KR20180006416A (pt) |
| CN (1) | CN107949401A (pt) |
| AU (2) | AU2016259868B2 (pt) |
| BR (1) | BR112017024073A2 (pt) |
| CA (1) | CA2984722A1 (pt) |
| HK (1) | HK1251473A1 (pt) |
| IL (1) | IL255582A (pt) |
| MX (1) | MX2017014481A (pt) |
| RU (2) | RU2020134183A (pt) |
| WO (1) | WO2016181225A2 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3108236A1 (en) * | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| JOP20210233A1 (ar) * | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| BRPI0508286B8 (pt) * | 2004-03-31 | 2021-05-25 | Dana Farber Cancer Inst Inc | método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| LT2782598T (lt) * | 2011-11-23 | 2020-07-27 | In3Bio Ltd. | Rekombinantiniai baltymai ir jų terapinis panaudojimas |
| RU2747857C2 (ru) | 2013-03-15 | 2021-05-17 | Ин3Био Лтд. | Самособирающиеся синтетические белки |
-
2016
- 2016-03-17 US US15/073,021 patent/US20160333087A1/en active Pending
- 2016-05-12 KR KR1020177035561A patent/KR20180006416A/ko unknown
- 2016-05-12 CN CN201680038424.4A patent/CN107949401A/zh active Pending
- 2016-05-12 BR BR112017024073-4A patent/BR112017024073A2/pt active Search and Examination
- 2016-05-12 EP EP16741385.5A patent/EP3294327A2/en active Pending
- 2016-05-12 JP JP2017559450A patent/JP7291987B2/ja active Active
- 2016-05-12 MX MX2017014481A patent/MX2017014481A/es unknown
- 2016-05-12 CA CA2984722A patent/CA2984722A1/en active Pending
- 2016-05-12 AU AU2016259868A patent/AU2016259868B2/en active Active
- 2016-05-12 RU RU2020134183A patent/RU2020134183A/ru unknown
- 2016-05-12 RU RU2017143182A patent/RU2735493C2/ru active
- 2016-05-12 WO PCT/IB2016/000888 patent/WO2016181225A2/en active Application Filing
-
2017
- 2017-11-09 IL IL255582A patent/IL255582A/en unknown
-
2018
- 2018-08-27 HK HK18111019.4A patent/HK1251473A1/zh unknown
-
2021
- 2021-06-25 US US17/358,788 patent/US20220041704A1/en active Pending
- 2021-10-08 JP JP2021166346A patent/JP2022027658A/ja active Pending
- 2021-11-26 AU AU2021273638A patent/AU2021273638A1/en not_active Abandoned
-
2023
- 2023-12-22 JP JP2023217218A patent/JP2024041781A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016259868B2 (en) | 2021-09-23 |
| RU2017143182A3 (pt) | 2019-11-13 |
| AU2016259868A1 (en) | 2017-11-23 |
| EP3294327A2 (en) | 2018-03-21 |
| IL255582A (en) | 2018-01-31 |
| CA2984722A1 (en) | 2016-11-17 |
| US20220041704A1 (en) | 2022-02-10 |
| KR20180006416A (ko) | 2018-01-17 |
| RU2020134183A (ru) | 2020-12-01 |
| JP2022027658A (ja) | 2022-02-10 |
| US20160333087A1 (en) | 2016-11-17 |
| MX2017014481A (es) | 2018-03-02 |
| CN107949401A (zh) | 2018-04-20 |
| WO2016181225A2 (en) | 2016-11-17 |
| HK1251473A1 (zh) | 2019-02-01 |
| JP7291987B2 (ja) | 2023-06-16 |
| RU2017143182A (ru) | 2019-06-13 |
| JP2024041781A (ja) | 2024-03-27 |
| JP2018515539A (ja) | 2018-06-14 |
| WO2016181225A3 (en) | 2017-01-12 |
| RU2735493C2 (ru) | 2020-11-03 |
| AU2021273638A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021002145A2 (pt) | Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico | |
| BR112013029385A2 (pt) | método para tratamento combinado de câncer dirigido contra egfr | |
| MX2022005994A (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2014000130A (es) | Procedimientos y composiciones para la inhibicion de resorcion osea. | |
| BR112019006228A2 (pt) | tratamento de câncer de próstata | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| MX2021011110A (es) | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| RU2017120184A (ru) | Лекарства для замедления течения болезни паркинсона | |
| MX2019001467A (es) | Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer. | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| WO2015035410A8 (en) | Cancer therapy | |
| BR112017024073A2 (pt) | métodos e composições para a inibição da via egf/egfr em combinação com inibidores de tirosina quinase | |
| BR112015012497A2 (pt) | combinações farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |